https://orcid.org/0000-0002-1948-8515
TO THE EDITOR:
Tyrosine kinase inhibitors (TKIs) have profoundly affected the outcome of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).1-7 In the recent front-line GIMEMA LAL2116 protocol for adult patients with Ph+ ALL, with no upper age limit, induction of dasatinib was followed by a consolidation with 2 to 5 cycles of the bispecific monoclonal antibody blinatumomab.8,9
With this targeted and immunotherapeutic induction-consolidation strategy devoid of systemic chemotherapy, a complete hematologic response was observed in 98.4% of cases and a molecular response, identified by the number of BCR/ABL1 copies in 60% of patients after 2 cycles of blinatumomab, the primary end point of the study.10 Molecular responses further increased after additional blinatumomab cycles. Overall survival and disease-free survival were 95.2% and 88.3%, respectively, at a median follow-up of 18 months.10 We hereby report extensive...
REFERENCES
1.
Ravandi
F.
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia
. Blood.
2019
;133
(2
):130
-136
.2.
Rousselot
P
, Coudé
MM
, Gokbuget
N
, et al; European Working Group on Adult ALL (EWALL) group
. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
. Blood.
2016
;128
(6
):774
-782
.3.
Yoon
JH
, Yhim
HY
, Kwak
JY
, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia
. Ann Oncol.
2016
;27
(6
):1081
-1088
.4.
Vignetti
M
, Fazi
P
, Cimino
G
, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol
. Blood.
2007
;109
(9
):3676
-3678
.5.
Foà
R
, Vitale
A
, Vignetti
M
, et al; GIMEMA Acute Leukemia Working Party
. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
. Blood.
2011
; 118
(25
):6521
-6528
.6.
Chiaretti
S
, Vitale
A
, Vignetti
M
, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
. Haematologica.
2016
;101
(12
):1544
-1552
.7.
Chiaretti
S
, Ansuinelli
M
, Vitale
A
, et al. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol
. Haematologica.
2021
;106
(7
):1828
-1838
.8.
Kantarjian
H
, Stein
A
, Gökbuget
N
, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
. N Engl J Med.
2017
;376
(9
):836
-847
.9.
Topp
MS
, Gökbuget
N
, Zugmaier
G
, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
. J Clin Oncol.
2014
;32
(36
):4134
-4140
.10.
Foà
R
, Bassan
R
, Vitale
A
, et al. Dasatinib-blinatumomab treatment for adult Ph-positive acute lymphoblastic leukemia in adults
. N Engl J Med.
2020
;383
(17
):1613
-1623
.11.
Chiaretti
S
, Bassan
R
, Vitale
A
, et al. Updated results of the GIMEMA LAL2116 D-ALBA trial for newly diagnosed adults with Ph+ ALL [abstract]
. HemaSphere.
2021
;5
(S2
):e566
. Abstract S112.12.
Trabolsi
A
, Arumov
A
, Schatz
JH.
T cell-activating bispecific antibodies in cancer therapy
. J Immunol.
2019
;203
(3
):585
-592
.13.
Willinger
T
, Freeman
T
, Hasegawa
H
, McMichael
AJ
, Callan
MF.
Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets
. J Immunol.
2005
;175
(9
):5895
-5903
.14.
Torelli
GF
, Guarini
A
, Maggio
R
, Alfieri
C
, Vitale
A
, Foà
R.
Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission
. Haematologica.
2005
;90
(6
):785
-792
.15.
Torelli
GF
, Peragine
N
, Raponi
S
, et al. Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells
. Haematologica.
2014
;99
(7
):1248
-1254
.16.
Torelli
GF
, Peragine
N
, Mariglia
P
, Foà
R.
The antileukemic potential of natural killer cells
. Immunotherapy.
2016
;8
(4
):425
-434
.17.
Mustjoki
S
, Auvinen
K
, Kreutzman
A
, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
. Leukemia.
2013
;27
(4
): 914
-924
.18.
Kim
DH
, Kamel-Reid
S
, Chang
H
, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
. Haematologica.
2009
;94
(1
):135
-139
.19.
Mustjoki
S
, Ekblom
M
, Arstila
TP
, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
. Leukemia.
2009
;23
(8
):1398
-1405
.20.
Zugmaier
G
, Gökbuget
N
, Klinger
M
, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
. Blood.
2015
;126
(4
):2578
-2584
.21.
Dwarakanath
BS
, Farooque
A
, Gupta
S.
Targeting regulatory T cells for improving cancer therapy: Challenges and prospects
. Cancer Rep (Hoboken).
2018
;1
(1
):e21105
.22.
Suryadevara
CM
, Desai
R
, Farber
SH
, et al. Preventing Lck activation in CAR T cells confers Treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts
. Clin Cancer Res.
2019
;25
(1
):358
-368
.23.
Duell
J
, Dittrich
M
, Bedke
T
, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
. Leukemia.
2017
;31
(10
):2181
-2190
.24.
Niedźwiecki
M
, Budziło
O
, Adamkiewicz-Drożyńska
E
, et al. CD4+CD25highCD127low/FoxP3+ regulatory T-cell population in acute leukemias: a review of the literature
. J Immunol Res.
2019
;2019
:2816498
.25.
Leonard
JT
, Kosaka
Y
, Malla
P
, et al. Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL
. Blood.
2021
;137
(7
):939
-944
. .26.
Batlevi
CL
, Matsuki
E
, Brentjens
RJ
, Younes
A.
Novel immunotherapies in lymphoid malignancies
. Nat Rev Clin Oncol.
2016
;13
(1
):25
-40
.27.
Chiaretti
S
, Vitale
A
, Cazzaniga
G
, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts
. Haematologica.
2013
;98
(11
):1702
-1710
.© 2021 by The American Society of Hematology
2021
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal